A Systematic Review of the Comparative Safety of Colloids

Archives of Surgery

Volumn 139, Issue 5, 2004, Pages 552-563

  Barron, Michael E ^a   Wilkes, Mahlon M ^b   Navickis, Roberta J ^b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b Hygeia Associates   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; DEXTRAN; GELATIN; HETASTARCH; OXYPOLYGELATIN;

ACUTE DISEASE; ANAPHYLAXIS; BLEEDING; BLOOD CLOTTING DISORDER; CLINICAL TRIAL; COHORT ANALYSIS; COLLOID; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA BASE; DISEASE SEVERITY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FLUID THERAPY; HUMAN; ISCHEMIA; KIDNEY FAILURE; LIVER DYSFUNCTION; MEDICAL LITERATURE; MEDLINE; META ANALYSIS; MORBIDITY; MORTALITY; PRIORITY JOURNAL; PRURITUS; REVIEW; SIDE EFFECT;

ALBUMINS; COLLOIDS; DEXTRANS; FLUID THERAPY; GELATIN; HETASTARCH; HUMANS; ODDS RATIO; PLASMA SUBSTITUTES; PRURITUS;

EID: 2342616812     PISSN: 00040010     EISSN: None     Source Type: Journal    
DOI: 10.1001/archsurg.139.5.552     Document Type: Review

References (114)

1. Prien T, Backhaus N, Pelster F, Pircher W, Bünte H, Lawin P. Effect of intraoperative fluid administration and colloid osmotic pressure on the formation of intestinal edema during gastrointestinal surgery. J Clin Anesth. 1990;2:317-323.
2. Ring J, Messmer K. Incidence and severity of anaphylactoid reactions to colloid volume substitutes. Lancet. 1977;1:466-469.
3. Mastroianni L, Low HB, Rollman J, Wagle M, Bleske B, Chow MS. A comparison of 10% pentastarch and 5% albumin in patients undergoing open-heart surgery. J Clin Pharmacol. 1994;34:34-40.
4. London MJ, Ho JS, Triedman JK, et al. A randomized clinical trial of 10% pentastarch (low molecular weight hydroxyethyl starch) versus 5% albumin for plasma volume expansion after cardiac operations. J Thorac Cardiovasc Surg. 1989;97:785-797.
5. Janeway CA, Gibson ST, Woodruff LM, Heyl JT, Bailey OT, Newhouser LR. Chemical, clinical, and immunological studies on the products of human plasma fractionation, VII: concentrated human serum albumin. J Clin Invest 1944;23:465-490.
6. Lundsgaard-Hansen P, Tschirren B. Clinical experience with 120,000 units of modified fluid gelatin. Dev Biol Stand. 1980;48:251-256.
7. Quast U, Welge-Lüssen U, Sedlacek HH. Adverse reactions in connection with albumin and other plasma substitutes. Dev Biol Stand. 1980;48:131-142.
8. Schöning B, Lorenz W. Prevention of allergoid (cutaneous anaphylactoid) reactions to polygeline (Haemaccel) in orthopaedic patients by premedication with H1- and H2-receptor antagonists. Dev Biol Stand. 1980;48:241-249.
9. Diehl JT, Lester JL, Cosgrove DM. Clinical comparison of hetastarch and albumin in postoperative cardiac patients. Ann Thorac Surg. 1982;34:674-679.
10. Kassell NF, Peerless SJ, Durward QJ, Beck DW, Drake CG, Adams HP. Treatment of ischemic deficits from vasospasm with intravascular volume expansion and induced arterial hypertension. Neurosurgery. 1982;11:337-343.
11. Palanzo OA, Parr GV, Bull AP, Williams DR, O'Neill MJ, Waldhausen JA. Hetastarch as a prime for cardiopulmonary bypass. Ann Thorac Surg. 1982;34:680-683.
12. Blanloeil Y, Gunst JP, Spreux A, Cozian A, Dixneuf B. Accidents anaphylactoïdes sévères après perfusion d'une gélatine fluide modifiée en solution équilibrée: deux études prospectives. Therapie. 1983;38:539-546.
13. Moggio RA, Rha CC, Somberg ED, Praeger PI, Pooley RW, Reed GE. Hemodynamic comparison of albumin and hydroxyethyl starch in postoperative cardiac surgery patients. Crit Care Med. 1983;11:943-945.
14. Rackow EC, Falk JL, Fein IA, at al. Fluid resuscitation in circulatory shock: a comparison of the cardiorespiratory effects of albumin, hetastarch, and saline solutions in patients with hypovolemic and septic shock. Crit Care Med. 1983;11:839-850.
15. Saunders CR, Carlisle L, Bick RL. Hydroxyethyl starch versus albumin in cardiopulmonary bypass prime solutions. Ann Thorac Surg. 1983;36:532-539.
16. Weis KH. Haemaccel 35: Nebenreaktionen in einer multizentrischen, prospektiven Studie. Anaesthesist. 1983;32:488-493.
17. Kirklin JK, Lell WA, Kouchoukos NT. Hydroxyethyl starch versus albumin for colloid infusion following cardiopulmonary bypass in patients undergoing myocardial revascularization. Ann Thorac Surg. 1984;37:40-46.
18. Pfeifer U, Kult J, Forster H. Ascites als Komplikation hepatischer Speicherung von Hydroxyathylstärke (HES) bei Langzeitdialyse. Klin Wochenschr. 1984;62:862-866.
19. Schöning B, Sommer K, Koch H. Herzstillstand unter Dextraninfusion trotz Haptenhemmung. Anasth Intensivther Notfallmed. 1984;19:34-38.
20. Gallagher JD, Moore RA, Kerns D, et al. Effects of colloid or crystalloid administration on pulmonary extravascular water in the postoperative period after coronary artery bypass grafting. Anesth Analg. 1985;64:753-758.
21. Harris WH, Athanasoulis CA, Waltman AC, Salzman EW. Prophylaxis of deep-vein thrombosis after total hip replacement: dextran and external pneumatic compression compared with 1.2 or 0.3 gram of aspirin daily. J Bone Joint Surg Am. 1985;67:57-62.
22. Sade RM, Stroud MR, Crawford FA, Kratz JM, Dearing JP, Bartles DM. A prospective randomized study of hydroxyethyl starch, albumin, and lactated Ringer's solution as priming fluid for cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1985;89:713-722.
23. Boldt J, von Bormann B, Kling D, Borner U, Mulch J, Hempelmann G. Volumenersatz mit einem neuen Hydroxyäthylstärke-Präparat (3% HÄS 200/0,5) in der Herzchirurgie. Infusionsther Klin Ernahr. 1986;13:145-151.
24. Dawidson I, Berglin E, Brynger H, Reisch J. Intravascular volumes and colloid dynamics in relation to fluid management in living related kidney donors and recipients. Crit Care Med. 1987;15:631-636.
25. Lumb PD. A comparison between 25% albumin and 6% hydroxyethyl starch solutions on lung water accumulation during and immediately after cardiopulmonary bypass. Ann Surg. 1987;206:210-213.
26. Paull J. A prospective study of dextran-induced anaphylactoid reactions in 5745 patients. Anaesth Intensive Care. 1987;15:163-167.
27. Iacono RP, Linford J, Toole JG. Use of hetastarch for volume expansion [letter]. J Neurosurg. 1987;66:635-637.
28. Turner PJ, Young IF, Marley PB, Herrington RW, Schiff P. Albumin solutions: their production and quality control. Dev Biol Stand. 1987;67:119-127.
29. Falk JL, Rackow EC, Astiz ME, Weil MH. Effects of hetastarch and albumin on coagulation in patients with septic shock. J Clin Pharmacol. 1988;28;412-415.
30. Fujii H. Plasma exchange using dextran 40-electrolyte solution as the sole replacement fluid in malignant paraproteinemia. Transfusion. 1988;28:42-45.
31. Köppel C, Baudisch H, Ibe K. Inadvertent metal loading of critically ill patients with acute renal failure by human albumin solution infusion therapy. J Toxicol Clin Toxicol. 1988;26:337-356.
32. Hemodilution in Stroke Study Group. Hypervolemic hemodilution treatment of acute stroke: results of a randomized multicenter trial using pentastarch. Stroke. 1989;20:317-323.
33. Mercatello A, Laville M, Leizorovicz A. Effets indésirables des échanges plasmatiques thérapeutiques: étude prospective contrölée. Presse Med. 1989;18:325-329.
34. Rackow EC, Mecher C, Astiz ME, Griffel M, Falk JL, Weil MH. Effects of pentastarch and albumin infusion on cardiorespiratory function and coagulation in patients with severe sepsis and systemic hypoperfusion. Crit Care Med. 1989;17:394-398.
35. Bergonzi G, Paties C, Vassallo G, et al. Dextran deposits in tissues of patients undergoing haemodialysis. Nephrol Dial Transplant. 1990;5:54-58.
36. Gold MS, Russo J, Tissot M, Weinhouse G, Riles T. Comparison of hetastarch to albumin for perioperative bleeding in patients undergoing abdominal aortic aneurysm surgery: a prospective, randomized study. Ann Surg. 1990;211:482-485.
37. Levy I, Merlob P, Ashkenazi S, Reisner SH. Neonatal polycythaemia: effect of partial dilutional exchange transfusion with human albumin on whole blood viscosity. Eur J Pediatr. 1990;149:354-355.
38. Planas R, Ginès P, Arroyo V, et al. Dextran-70 versus albumin as plasma expanders in cirrhotic patients with tense ascites treated with total paracentesis: results of a randomized study. Gastroenterology. 1990;99:1736-1744.
39. Heilmann L, Heitz R, Koch FU, Ose C. Die perioperative Thromboseprophylaxe beim Kaiserschnitt: Ergebnisse einer randomisierten prospektiven Vergleichsuntersuchung mit 6% Hydroxyäthylstärke 0,62 und low-dose-Heparin. Z Geburtshilfe Perinatol. 1991;195:10-15.
40. Heilmann L, Lorch E, Hojnacki B, Müntefering H, Förster H. Die Speicherung von zwel unterschiedlichen Hydroxyäthylstärke-Prä paraten in der Plazenta nach Hämodilution bei Patientinnen mit fetaler Mangelentwicklung oder Schwangerschaftshochdruck. Infusionstherapie. 1991;18:236-243.
41. Himpe D, Van Cauwelaert P, Neels H, et al. Priming solutions for cardiopulmonary bypass: comparison of three colloids. J Cardiothorac Vasc Anesth. 1991;5:457-466.
42. Kaniecki K, Biesel E, Zielke E. Untersuchungen zur Verträglighkeit von Haemofusin in der Hämodilution und Volumensubstitution. Infusionstherapie. 1991;18:306-309.
43. Mast H, Marx P. Neurological deterioration under isovolemic hemodilution with hydroxyethyl starch in acute cerebral ischemia. Stroke. 1991;22:680-683.
44. Salemo F, Badalamenti S, Lorenzano E, Moser P, Incerti P. Randomized comparative study of hemaccel vs albumin infusion after total paracentesis in cirrhotic patients with refractory ascites. Hepatology. 1991;13:707-713.
45. Albegger K, Schneeberger R, Franke V, Oberascher G, Miller K. Juckreiz nach Therapie mit Hydroxyäthylstärke (HES) bei otoneurologischen Erkrankungen. Wien Med Wochenschr. 1992;142:1-7.
46. Boldt J, Zickmann B, Ballesteros BM, Stertmann F, Hempelmann G. Influence of five different priming solutions on platelet function in patients undergoing cardiac surgery. Anesth Analg. 1992;74:219-225.
47. Fassio E, Terg R, Landeira G, et al. Paracentesis with Dextran 70 vs paracentesis with albumin in cirrhosis with tense ascites: results of a randomized study. J Hepatol. 1992;14:310-316.
48. London MJ, Franks M, Verrier ED, Merrick SH, Levin J, Mangano DT. The safety and efficacy of ten percent pentastarch as a cardiopulmonary bypass priming solution: a randomized clinical trial. J Thorac Cardiovasc Surg. 1992;104:284-296.
49. Villarino ME, Gordon SM, Valdon C, et al. A cluster of severe postoperative bleeding following open heart surgery. Infect Control Hosp Epidemiol. 1992;13:282-287.
50. Boldt J, Knothe C, Zickmann B, Andres P, Dapper F, Hempelmann G. Influence of different intravascular volume therapies on platelet function in patients undergoing cardiopulmonary bypass. Anesth Analg. 1993;76:1185-1190.
51. Boldt J, Knothe C, Schindler E, Hammermann H, Dapper F, Hempelmann G. Volume replacement with hydroxyethyl starch solution in children. Br J Anaesth. 1993;70:661-665.
52. Gall H, Kaufmann R, von Ehr M, Schumann K, Sterry W. Persistlerender Pruritus nach Hydroxyäthylstärke-Infusionen: retrospektive Langzeitstudie an 266 Fällen. Hautarzt. 1993;44:713-716.
53. Grundmann T, Gramer L. Pruritus bei Infusionstherapie mit Hydroxyethylstärke verschledener Menge. Wehrmed Monatsschr. 1993;2:47-48.
54. Haws RM, Baum M. Efficacy of albumin and diuretic therapy in children with nephrotic syndrome. Pediatrics. 1993;91:1142-1146.
55. Jurecka W, Szepfalusi Z, Parth E, et al. Hydroxyethylstarch deposits in human skin: a model for pruritus? Arch Dermatol Res. 1993;285:13-19.
56. Videm V, Fosse E, Svennevig JL. Platelet preservation during coronary bypass surgery with bubble and membrane oxygenators: effect of albumin priming. Perfusion. 1993;8:409-415.
57. Laxenaire MC, Charpentier C, Feldman L. Réaction anaphylactoïdes aux substituts colloïdaux du plasma: incidence, facteurs de risque, mécanismses: enquête prospective multicentrique française. Ann Fr Anesth Reanim. 1994;13:301-310.
58. Desloovere C, Knecht R. Infusionstherapie bei Hörsturz: Reduktion des Juckreizrisikos nach Hydroxyethylstärke (HES) unter Erhalt des Therapieerfolges: eine prospektive randomisierte Studie. Laryngorhinootologie. 1995;74:468-472.
59. Leunig A, Szeimies RM, Wilmes E, Gutmann R, Stolz W, Feyh J. Klinische und elektronenmikroskopische Untersuchung zur Hörsturztherapie mit der Kombination 10% HES 200/0.5 und Pentoxifyllin. Laryngorhinootologie. 1995;74:135-140.
60. Tabuchi N, de Haan J, Gallandat Huet RC, Boonstra PW, van Oevaren W. Gelatin use impairs platelet adhesion during cardiac surgery. Thromb Haemost 1995;74:1447-1451.
61. Treib J, Haass A, Pindur G, et al. HES 200/0.5 is not HES 200/0.5: influence of the C2/C6 hydroxyethylation ratio of hydroxyethyl starch (HES) on hemorheology, coagulation and elimination kinetics. Thromb Haemost 1995;74:1452-1456.
62. Trumble ER, Muizelaar JP, Myseros JS, Choi SC, Warren BB. Coagulopathy with the use of hetastarch in the treatment of vasospasm. J Neurosurg. 1995;82:44-47.
63. Tølløfsrud S, Svennevig JL, Breivik H, et al. Fluid balance and pulmonary functions during and after coronary artery bypass surgery: Ringer's acetate compared with dextran, polygeline, or albumin. Acta Anaesthesiol Scand. 1995;39:671-677.
64. Bernard C, Alain M, Simone C, Xavier M, Jean-Francois M. Hydroxyethylstarch and osmotic nephrosis-like lesions in kidney transplants [letter]. Lancet. 1996;348:1595.
65. Brutocao D, Bratton SL, Thomas JR, Schrader PF, Coles PG, Lynn AM. Comparison of hetastarch with albumin for postoperative volume expansion in children after cardiopulmonary bypass. J Cardiothorac Vasc Anesth. 1998;10:348-351.
66. Cittanova ML, Leblanc I, Legendre C, Mouquet C, Riou B, Coriat P. Effect of hydroxyethylstarch in brain-dead kidney donors on renal function in kidney-transplant recipients. Lancet. 1996;348:1620-1622.
67. Ginès A, Fernández-Esparrach G, Monescillo A, et al. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology. 1996;111:1002-1010.
68. Schneider M, Valentine S, Clarke GM, Newman MA, Peacock J. Acute renal failure in cardiac surgical patients, potentiated by gentamicin and calcium. Anaesth Intensive Care. 1996;24:647-650.
69. Treib J, Haass A, Pindur G, et al. Influence of low and medium molecular weight hydroxyethyl starch on platelets during a long-term hemodilution in patients with cerebrovascular diseases. Arzneimittelforschung. 1996;46:1064-1066.
70. Treib J, Haass A, Pindur G, Treib W, Wenzel E, Schimrigk K. Influence of intravascular molecular weight of hydroxyethyl starch on platelets. Eur J Haematol. 1996;56:168-172.
71. Wahba A, Sendtner E, Birnbaum DE. Fluid resuscitation with Haemaccel vs human albumin following coronary artery bypass grafting. Thorac Cardiovasc Surg. 1996;44:178-182.
72. Biesenbach G, Kaiser W, Zazgornik J. Incidence of acute oligoanuric renal failure in dextran 40 treated patients with acute ischemic stroke stage III or IV. Ren Fail. 1997;19:69-75.
73. Cope JT, Banks D, Mauney MC, et al. Intraoperative hetastarch infusion impairs hemostasis after cardiac operations. Ann Thorac Surg. 1997;63:78-82.
74. Dehne MG, Mühling J, Sablotzki A, Papke G, Kuntzsch U, Hempelmann G. Einfluß von Hydroxyethylstärke-Lösung auf die Nierenfunktion bei operativen Intensivpatienten. Anasthesiol Intensivmed Notfallmed Schmerzther. 1997;32:348-354.
75. Hedin H, Ljungström KG. Prevention of dextran anaphylaxis: ten years experience with hapten dextran. Int Arch Allergy Immunol. 1997;113:358-359.
76. Metze D, Reimann S, Szepfalusi Z, Bohle B, Kraft D, Luger TA. Persistent pruritus after hydroxyethyl starch infusion therapy: a result of long-term storage in cutaneous nerves. Br J Dermatol. 1997;136:553-559.
77. Owen HG, Brecher ME. Partial colloid starch replacement for therapeutic plasma exchange. J Clin Apheresis. 1997;12:87-92.
78. Rock G, Sutton DM, Freedman J, Nair RC. Pentastarch instead of albumin as replacement fluid for therapeutic plasma exchange: the Canadian Apheresis Group. J Clin Apheresis. 1997;12:165-169.
79. Saxena N, Chauhan S, Ramesh GS. A comparison of hetastarch, albumin and Ringer lactate for volume replacement in coronary artery bypass surgery. J Anaesth Clin Pharm. 1997;13:117-120.
80. Stoll M, Treib J, Schenk JF, et al. No coagulation disorders under high-dose volume therapy with low-molecular-weight hydroxyethyl starch. Haemostasis. 1997;27:251-258.
81. Tigchelaar I, Gallandat Huet RC, Korsten J, Boonstra PW, van Oeveren W. Hemostatic effects of three colloid plasma substitutes for priming solution in cardiopulmonary bypass. Eur J Cardiothorac Surg. 1997;11:626-632.
82. Treib J, Haass A, Pindur G, et al. Increased haemorrhagic risk after repeated infusion of highly substituted medium molecular weight hydroxyethyl starch. Arzneimittelforschung. 1997;47:18-22.
83. Altman C, Bernard B, Roulot D, Vitte RL, Ink O. Randomized comparative multicenter study of hydroxyethyl starch versus albumin as a plasma expander in cirrhotic patients with tense ascites treated with paracentesis. Eur J Gastroenterol Hepatol. 1998;10:5-10.
84. Bothner U, Georgieff M, Vogt NH. Assessment of the safety and tolerance of 6% hydroxyethyl starch (200/0.5) solution: a randomized, controlled epidemiology study. Anesth Analg. 1998;86:850-855.
85. Cochrane Injuries Group Albumin Reviewers. Human albumin administration in critically ill patients: systematic review of randomised controlled trials. BMJ. 1998;317:235-240.
86. Gröchenig E, Albegger K, Dieterich HJ, et al. Hydroxyethylstarch-related pruritus: a prospective multicentre Investigation of 544 patients. Perfusion. 1998;11:62-69.
87. Herwaldt LA, Swartzendruber SK, Edmond MB, et al. The epidemiology of hemorrhage related to cardiothoracic operations. Infect Control Hosp Epidemiol. 1998;19:9-16.
88. Tigchelaar I, Gallandat Huet RC, Boonstra PW, van Oeveren W. Comparison of three plasma expanders used as priming fluids in cardiopulmonary bypass patients. Perfusion. 1998;13:297-303.
89. Deman A, Peeters P, Sennesael J. Hydroxyethyl starch does not impair immediate renal function in kidney transplant recipients: a retrospective, multicentre analysis. Nephrol Dial Transplant. 1999;14:1517-1520.
90. Goss GA, Weinstein R. Pentastarch as partial replacement fluid for therapeutic plasma exchange: effect on plasma proteins, adverse events during treatment and serum ionized calcium. J Clin Apheresis. 1999;14:114-121.
91. Karoutsos S, Nathan N, Lahrimi A, Grouille D, Feiss P, Cox DJ. Thrombelastogram reveals hypercoagulability after administration of gelatin solution. Br J Anaesth. 1999;82:175-177.
92. Keyser EJ, Latter DA, Morin JE, Murshid AA, Denis F, de Varennes B. Pentastarch versus albumin in cardiopulmonary bypass prime: impact on blood loss. J Card Surg. 1999;14:279-286.
93. Kumle B, Boldt J, Piper S, Schmidt C, Suttner S, Salopek S. The influence of different intravascular volume replacement regimens on renal function in the elderly. Anesth Analg. 1999;89:1124-1130.
94. Omar MN, Shouk TA, Khaleq MA. Activity of blood coagulation and fibrinolysis during and after hydroxyethyl starch (HES) colloidal volume replacement. Clin Biochem. 1999;32:269-274.
95. Sharland C, Huggett A, Nielson MS, Friedmann PS. Persistent pruritis after pentastarch infusions in intensive care patients. Anaesthesia. 1999;54:500-501.
96. Sirtl C, Laubenthal H, Zumtobel V, Kraft D, Jurecka W. Tissue deposits of hydroxyethyl starch (HES): dose-dependent and time-related. Br J Anaesth. 1999;82:510-515.
97. Canver CC, Nichols RD. Use of intraoperative hetastarch priming during coronary bypass. Chest. 2000;118:1616-1620.
98. Knutson JE, Deering JA, Hall FW, et al. Does intraoperative hetastarch administration increase blood loss and transfusion requirements after cardiac surgery? Anesth Analg. 2000;90:801-807.
99. Morgan PW, Berridge JC. Giving long-persistent starch as volume replacement can cause pruritus after cardiac surgery. Br J Anaesth. 2000;85:696-699.
100. Torchia MG, Danzinger RG. Perioperative blood transfusion and albumin administration are independent risk factors for the development of postoperative infections after colorectal surgery. Can J Surg. 2000;43:212-216.
101. Christidis C, Mal F, Ramos J, et al. Worsening of hepatic dysfunction as a consequence of repeated hydroxyethylstarch infusions. J Hepatol. 2001;35:726-732.
102. Howard G, Downward G, Bowie D. Human serum albumin induced hypotension in the postoperative phase of cardiac surgery. Anaesth Intensive Care. 2001;29:591-594.
103. Huraux C, Ankri AA, Eyraud D, et al. Hemostatic changes in patients receiving hydroxyethyl starch: the influence of ABO blood group. Anesth Analg. 2001;92:1396-1401.
104. Jonville-Béra AP, Autret-Leca E, Gruel Y. Acquired type I von Willebrand's disease associated with highly substituted hydroxyethyl starch. N Engl J Med. 2001;345:622-623.
105. Kimme P, Jannsen B, Ledin T, Gupta A, Vegfors M. High incidence of pruritus after large doses of hydroxyethyl starch (HES) infusions. Acta Anaesthesiol Scand. 2001;45:686-689.
106. Murphy M, Carmichael AJ, Lawler PG, White M, Cox NH. The incidence of hydroxyethyl starch-associated pruritus. Br J Dermatol. 2001;144:973-976.
107. Petroni KC, Green R, Birmingham S. Hextend is a safe alternative to 5% human albumin for patients undergoing elective cardiac surgery [abstract]. Anesthesiology. 2001;95:A198.
108. Schortgen F, Lacherade JC, Bruneel F, et al. Effects of hydroxyethylstarch and gelatin on renal function in severe sepsis: a multicentre randomised study. Lancet. 2001;357:911-916.
109. Wilkes MM, Navickis RJ, Sibbald WJ. Albumin versus hydroxyethyl starch in cardiopulmonary bypass surgery: a meta-analysis of postoperative bleeding. Ann Thorac Surg. 2001;72:527-534.
110. Wilkes MM, Navickis RJ. Patient survival after human albumin administration: a meta-analysis of randomized, controlled trials. Ann Intern Med. 2001;135:149-164.
111. von Hoegen I, Waller C. Safety of human albumin based on spontaneously reported serious adverse events. Crit Care Med. 2001;29:994-996.
112. Kuo ST, Hsu WC, Young YH. Dextran-induced pulmonary edema in patients with sudden deafness. Otol Neurotol. 2002;23:661-664.
113. Trull A, Hughes V, Cooper D, et al. Influence of albumin supplementation on tacrolimus and cyclosporine therapy early after liver transplantation. Liver Transpl. 2002;8:224-232.
114. Lucas CE, Weaver D, Higgins RF, Ledgerwood AM, Johnson SD, Bouwman DL. Effects of albumin versus non-albumin resuscitation on plasma volume and renal excretory function. J Trauma. 1978;18:564-570.